newsfilter
← Latest News
GlobeNewswire·

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

WOBURN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with post-acute